{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:56:15Z","timestamp":1792162575517,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T00:00:00Z","timestamp":1363132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s40264-013-0025-y","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T05:51:22Z","timestamp":1363067482000},"page":"237-246","source":"Crossref","is-referenced-by-count":35,"title":["Safety Profile of Modafinil Across a Range of Prescribing Indications, Including Off-Label Use, in a Primary Care Setting in England"],"prefix":"10.1007","volume":"36","author":[{"given":"Miranda","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,13]]},"reference":[{"key":"25_CR1","volume-title":"Assessment report for modafinil containing medicinal products","author":"European Medicines Agency (EMA)","year":"2011","unstructured":"European Medicines Agency (EMA). Assessment report for modafinil containing medicinal products. London: EMA; 2011."},{"key":"25_CR2","unstructured":"Cephalon Inc. Dear Healthcare Professional letter. Updated safety information: warnings regarding serious rash, including Stevens\u2013Johnson Syndrome and hypersensitivity reactions, and psychiatric symptoms. Silver Spring: US FDA. 2007. http:\/\/www.fda.gov\/medwatch\/safety\/2007\/Provigil_dhcpletter091207_final.pdf . Accessed May 2012."},{"key":"25_CR3","volume-title":"Summary of product characteristics: Provigil\u00ae","author":"Cephalon (UK) Limited","year":"2012","unstructured":"Cephalon (UK) Limited. Summary of product characteristics: Provigil\u00ae. Castleford: Cephalon UK Limited; 2012."},{"issue":"10","key":"25_CR4","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1176\/appi.ajp.162.10.1983","volume":"162","author":"JJ Mariani","year":"2005","unstructured":"Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005;162(10):1983.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"25_CR5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/01.jcp.0000185346.77966.a4","volume":"25","author":"S Ranjan","year":"2005","unstructured":"Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol. 2005;25(6):628\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"25_CR6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.162.4.813-a","volume":"162","author":"F Vorspan","year":"2005","unstructured":"Vorspan F, Warot D, Consoli A, Cohen D, Mazet P. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry. 2005;162(4):813\u20134.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"25_CR7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.163.3.549","volume":"163","author":"SP Kruszewski","year":"2006","unstructured":"Kruszewski SP. Euphorigenic and abusive properties of modafinil. Am J Psychiatry. 2006;163(3):549.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"25_CR8","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1176\/appi.ajp.162.10.1983-a","volume":"162","author":"N Oskooilar","year":"2005","unstructured":"Oskooilar N. A case of premature ventricular contractions with modafinil. Am J Psychiatry. 2005;162(10):1983\u20134.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"25_CR9","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1185\/030079906X148300","volume":"22","author":"SW Boellner","year":"2006","unstructured":"Boellner SW, Earl CQ, Arora S. Modafinil in children and adolescents with attention-deficit\/hyperactivity disorder: a preliminary 8-week, open-label study. Curr Med Res Opin. 2006;22(12):2457\u201365.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"25_CR10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1345\/aph.1H024","volume":"40","author":"SE Lindsay","year":"2006","unstructured":"Lindsay SE, Gudelsky GA, Heaton PC. Use of modafinil for the treatment of attention deficit\/hyperactivity disorder. Ann Pharmacother. 2006;40(10):1829\u201333.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"25_CR11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4088\/JCP.v67n0120","volume":"67","author":"JM Swanson","year":"2006","unstructured":"Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit\/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(1):137\u201347.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"25_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1389-9457(03)00162-X","volume":"4","author":"A Ivanenko","year":"2003","unstructured":"Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003;4(6):579\u201382.","journal-title":"Sleep Med"},{"issue":"12","key":"25_CR13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11593830-000000000-00000","volume":"34","author":"D Layton","year":"2011","unstructured":"Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34(12):e1\u20139.","journal-title":"Drug Saf"},{"key":"25_CR14","first-page":"329","volume-title":"Stephens\u2019 detection of new adverse drug reactions","author":"S Shakir","year":"2004","unstructured":"Shakir S. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens\u2019 detection of new adverse drug reactions.\u00a05th ed. Chichester: Wiley; 2004. p. 329\u201343.","edition":"5"},{"key":"25_CR15","unstructured":"CIOMS, WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: Switzerland. 2002. http:\/\/www.cioms.ch\/publications\/guidelines\/guidelines_nov_2002_blurb.htm . Accessed May 2012."},{"key":"25_CR16","unstructured":"Drug Safety Update. Monthly newsletter from MHRA. Vol 1. Issue 8, March 2008."},{"key":"25_CR17","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998; 43(1):88\u201397.","DOI":"10.1002\/ana.410430115"},{"key":"25_CR18","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000; 54(5):1166\u20135.","DOI":"10.1212\/WNL.54.5.1166"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-013-0025-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0025-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:28Z","timestamp":1559490088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-013-0025-y"}},"subtitle":["Results of a Modified Prescription-Event Monitoring Study"],"short-title":[],"issued":{"date-parts":[[2013,3,13]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s40264-013-0025-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,13]]}}}